Treatment-emergent adverse events associated with atypical antipsychotics

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 11, 2012, Pages 1587-1598

  Cha, Danielle S ^c   McIntyre, Roger S ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Adverse events; Atypical antipsychotics; Mood disorder; Side effects

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOZAPINE; HALOPERIDOL; ILOPERIDONE; LURASIDONE; OLANZAPINE; PLACEBO; PROLACTIN; QUETIAPINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADIPOCYTE; AGRANULOCYTOSIS; ANOREXIA NERVOSA; AUTISM; BLOOD DYSCRASIA; BODY FAT DISTRIBUTION; BODY WEIGHT; CARDIOMYOPATHY; CHOLESTEROL BLOOD LEVEL; DEMENTIA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSLIPIDEMIA; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GLUCOSE DISTURBANCE; GLUCOSE METABOLISM; HUMAN; HYPERPROLACTINEMIA; LACTATION; LEUKOPENIA; METABOLIC DISORDER; METABOLIC SYNDROME X; MYOCARDITIS; NEUROENDOCRINE DISEASE; NEUROEPILEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; NEUTROPENIA; ORTHOSTATIC DIZZINESS; PREGNANCY; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QT PROLONGATION; REPRODUCTIVE HEALTH; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; TREATMENT EMERGENT ADVERSE EVENT; WAIST CIRCUMFERENCE;

AFFECTIVE DISORDERS, PSYCHOTIC; ANTIPSYCHOTIC AGENTS; HUMANS; SAFETY-BASED DRUG WITHDRAWALS;

EID: 84863786711     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.656590     Document Type: Review

References (82)

1. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):28-36
2. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004;161:414-25
3. Pae CU. A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf 2009;8:373-86
4. Tandon R. Safety and tolerability: How do newer generation 'atypical' antipsychotics compare? Psychiatr Q 2002;73:297-311
5. Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: Focus on aripiprazole. Neuropsychiatr Dis Treat 2008;4:937-48
6. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 2011;10:35-43
7. Liauw SS, McIntyre RS. Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert Opin Pharmacother 2010;11:2827-37
8. Farmer CA, Aman MG. Aripiprazole for the treatment of irritability associated with autism. Expert Opin Pharmacother 2011;12:635-40
9. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43
10. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive summary. Crit Path Cardiol 2005;4:198-203
11. Cagampang FR, Poore KR, Hanson MA. Developmental origins of the metabolic syndrome: Body clocks and stress responses. Brain Behav Immun 2011;25:214-20
12. Findeisen HM, Weckbach S, Stark RG, et al. Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus. Cardiovasc Diabetol 2010;9:1-7
13. Prasad SB, Fahrtash F, Malaiapan Y, et al. Prevalence, detection, and management of the metabolic syndrome in patients with acute myocardial infarction: Role of an obesity-centric definition. Cardiol Res Pract 2010;2010:1-7
14. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as 'metabolic syndrome type 2'? Ann Clin Psychiatry 2007;19:257-64
15. Balf G, Stewart TD, Whitehead R, Baker RA. Metabolic adverse events in patients with mental illness treated with antipsychotics: A primary care perspective. Prim Care Companion J Clin Psychiatry 2008;10:15-24
16. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: Findings from the bipolar disorder center for Pennsylvanians. Bipolar Disord 2005;7:424-30
17. Fagiolini A, Frank E, Turkin S, et al. Metabolic syndrome in patients with bipolar disorder. J Clin Psychiatry 2008;69:678-9
18. McIntyre RS, Danilewitz M, Liauw SS, et al. Bipolar disorder and metabolic syndrome: An international perspective. J Affect Disord 2010;126(3):366-87 [Epub 2010 Jun 12]
19. Lieberman JA. Comparative effectiveness of antipsychotic drugs. A commentary on: COST Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 2006;63:1069-72
20. Baig MR, Navaira E, Escamilla MA, et al. Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: A possible mechanism for antipsychotic-induced metabolic alterations. J Psychiatr Pract 2010;16:325-33
21. Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig 2011;31:455-82
22. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 2008;371:1085-97
23. De HM, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011;26:144-58
24. Roy G, Bedard A, Desmarais PA, et al. Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naive French Canadian patients. J Child Adolesc Psychopharmacol 2010;20:479-87
25. Poirier P, Despres JP. Waist circumference, visceral obesity, and cardiovascular risk. J Cardiopulm Rehabil 2003;23:161-9
26. Baptista T, Serrano A, Uzcategui E, et al. The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: Comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela. Schizophr Res 2011;126:93-102
27. McIntyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 2008;162:929-35
28. Keitner GI. Adding atypical antipsychotics to antidepressants increases response in treatment-resistant major depression but increases discontinuation as a result of adverse events. Evid Based Med 2010;15:19-20
29. Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: Prevalence, monitoring and management. Bipolar Disord 2003;5(Suppl 2):62-79
30. Brecher M, Leong RW, Stening G, et al. Quetiapine and long-term weight change: A comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007;68:597-603
31. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39
32. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychoticinduced weight gain -mechanisms and genetics. J Psychopharmacol 2006;20(4 Suppl):15-18
33. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010;17:460-6
34. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26
35. Ucok A, Gaebel W. Side effects of atypical antipsychotics: A brief overview. World Psychiatry 2008;7:58-62
36. Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008;165:1281-8
37. Flament MF, Bissada H, Spettigue W. Evidence-based pharmacotherapy of eating disorders. Int J Neuropsychopharmacol 2011;18:1-19
38. Court A, Mulder C, Kerr M, et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: A pilot study. J Psychiatr Res 2010;44:1027-34
39. Gregoor JG, Van der Weide J, Loovers HM, et al. Association between LEP and LEPR gene polymorphisms and dyslipidemia in patients using atypical antipsychotic medication. Psychiatr Genet 2010;20:311-16
40. Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol 2011;51:631-8
41. Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006;164:672-81
42. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: Effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007;32:765-72
43. Henderson DC, Sharma B, Fan X, et al. Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. Ann Clin Psychiatry 2010;22:33-42
44. Kane JM, Sharif ZA. Atypical antipsychotics: Sedation versus efficacy. J Clin Psychiatry 2008;69(Suppl 1):18-31
45. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39
46. Miller DD. Atypical antipsychotics: Sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6(Suppl 2):3-7
47. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-41
48. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011;20:177-84
49. Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011;72(8):1063-71[Epub 2010 Oct 19]
50. Centorrino F, Price BH, Tuttle M, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002;159:109-15
51. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: Clinical features and management. Hum Psychopharmacol 2008;23(Suppl 1):15-26
52. Amann BL, Pogarell O, Mergl R, et al. EEG abnormalities associated with antipsychotics: A comparison of quetiapine, olanzapine, haloperidol and healthy subjects. Hum Psychopharmacol 2003;18:641-6
53. Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother 2009;43:785-91
54. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000;343:1388-98
55. Ucok A, Gaebel W. Side effects of atypical antipsychotics: A brief overview. World Psychiatry 2008;7:58-62
56. Yang FD, Wang XQ, Liu XP, et al. Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology (Berl) 2011;216:9-16
57. Nielsen J. The safety of atypical antipsychotics: Does QTc provide all the answers? Expert Opin Drug Saf 2011;10:341-4
58. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: Proven candidates and suspects. Curr Drug Saf 2010;5:97-104
59. Sala M. Vicentini A. Brambilla P. et al. QT interval prolongation related to psychoactive drug treatment: A comparison of monotherapy versus polytherapy Ann. Gen. Psychiatry 2005;4:1-6
60. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
61. Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 2008;69(Suppl 1):32-44
62. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 2004;64:2291-314
63. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22:1085-96
64. Knegtering H, Van den Bosch R, Castelein S, et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology 2008;33:711-17
65. Rettenbacher MA, Hofer A, Ebenbichler C, et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol 2010;30:711-15
66. Jerrell JM, Bacon J, Burgis JT, Menon S. Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents. J Adolesc Health 2009;45:70-6
67. Caccia S, Clavenna A, Bonati M. Antipsychotic drug toxicology in children. Expert Opin Drug Metab Toxicol 2011;7:591-608
68. Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008;23(Suppl 1):43-51
69. Nongpiur A, Praharaj SK, Sarkar S, Das B. Delayed onset of clozapine-induced leucopenia. Am J Ther. Lippincott Williams & Wilkins; 2010;1075-2765
70. Stergiou V, Bozikas VP, Garyfallos G, et al. Olanzapine-induced leucopenia and neutropenia. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:992-4
71. Shankar BR. Quetiapine-induced leucopenia and thrombocytopenia. Psychosomatics 2007;48:530-1
72. Buchman N, Strous RD, Ulman AM, et al. Olanzapine-induced leukopenia with human leukocyte antigen profiling. Int Clin Psychopharmacol 2001;16:55-7
73. Rahman A, Mican LM, Fischer C, Campbell AH. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother 2009;43:822-3
74. Nooijen PM, Carvalho F, Flanagan RJ. Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol 2011;26:112-19
75. Chandrasekaran PK. Agranulocytosis monitoring with clozapine patients: To follow guidelines or to attempt therapeutic controversies? Singapore Med J 2008;49:96-9
76. McCauley-Elsom K, Kulkarni J. Managing psychosis in pregnancy. Aust N Z J Psychiatry 2007;41:289-92
77. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009;15:183-92
78. Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother 2004;38:1265-71
79. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010;36:518-44
80. Iveli MF, Rebolledo A, Martin P, et al. Risperidone inhibits contractions induced by serotonin and histamine and reduces K+ currents in smooth muscle of human umbilical artery. Reprod Sci 2010;17:854-60
81. Hussar DA, Shah A. New drugs. Azilsartan medoxomil, belimumab, and lurasidone hydrochloride. J Am Pharm Assoc 2011;51:444-7
82. Gentile S. Infant safety with antipsychotic therapy in breast-feeding: A systematic review. J Clin Psychiatry 2008;69:666-73